OBI is a Taiwan-based biopharma company founded in 2002 with headquarters in Taipei and subsidiaries in the United States, China, Hong Kong, and Australia.

Founded in 1982, Orient EuroPharma (OEP) became officially listed in the Taiwan Exchange in 2003. In the beginning, the Company was a prescription drug distributor, but has now become a full-scale, multinational pharmaceutical company. The core competencies of the Company not only include pharmaceutical innovation, R&D, manufacturing, sales and clinical trials, but has significantly increased the Company's operational efficiency through vertical integration to provide customers with more complete services. In 2002, the consolidated revenue exceeded NTD 4.7 billion and the Company has nearly 1,000 employees worldwide, of which about 40% are overseas personnel.

Regardless of OEP headquarters, pharmaceutical factories, R&D centers or overseas subsidiaries, the dedication of the Company's supervisors and employees is evident. In an atmosphere that highly regards communication, not only are professionalism and data important, but respect towards people is greatly valued so that the condition and voices of its partners are always important. At work, the Company’s core value - Through Integrity, united we achieve and be remarkable, is manifested in every detail of the team effort to innovate and grow together.

In the field of protein drug design, the process of pegylation of the therapeutic protein preserve sits biologic activity by targeting the PEG polymer( polyethylene glycol) at a specific and a defined region on the protein. PharmaEssentia’s pegylation technology platform is designed to increase the protein drug’s efficacy by prolonging its circulation in the blood stream. Utilizing its innovative 40K PEG and its novel pegylation technology platform by combining protein engineering and PEG-related chemistry, PharmaEssentia creates novel product-Ropeginterferon alfa-2b for better disease treatment. Compared with similar drugs on the market, the long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties allowing once every two weeks administration offering improved tolerability and convenience. The marketing authorization for Ropeginterferon alfa-2b for treatment of PolycythemiaVera (PV) is granted by EMA in 2019 and Taiwan in May 2020.

The brand of 三合美 Food Co., Ltd. is "Pineapple Hill", which is located in Minxiong Township. We understand the value of pineapples, and it is our mission to let people know Taiwan pineapples. In order to improve the income of pineapple farmers,we plan a series of agricultural commodities to improve the
economic value of farming. Combining multiple industries such as bakedfoof, fermented food, daily necessities, health fo tourist attractions, we will give full play to the value of pineapple fields, actively promote the nutritional value of pineapples, and allow Taiwan pineapple to embark on a brand-new path for the
industry.

Precision Biotech Taiwan Corp., which was registered and established im 「Taiwan in 2017, is a world-leading professional institution for immunotherapy of cancer. Its self developed NKT autologous natural killer immune cell preparations PB101 has legally passed TFDA approved phase I clinical trial, and now entered phase II clinical trial.
Allogeneic NK immune cell preparations PB103 passed TFDA approved phase I/II clinical trial on August 26, 2020, and entered phase I/IIa clinical trial at the same time.
The special control law of Taiwan government allows patients to luse our PB101-103 series products for fee-based treatment,

Since 2022, Pythia Biotech Ltd. has advanced drug development with organ-on-chip technology. In 2023, we received tech transfer support from National Tsing Hua University and Taipei Medical University.
By biomimetic microenvironments for ex vivo drug evaluation, we enable more accurate, faster assessments of drug efficacy and toxicity. Reducing animal use, and accelerating drug development.